CN114917358A - 用于治疗癌症和炎症性疾病的偶联物和前药 - Google Patents

用于治疗癌症和炎症性疾病的偶联物和前药 Download PDF

Info

Publication number
CN114917358A
CN114917358A CN202210334259.4A CN202210334259A CN114917358A CN 114917358 A CN114917358 A CN 114917358A CN 202210334259 A CN202210334259 A CN 202210334259A CN 114917358 A CN114917358 A CN 114917358A
Authority
CN
China
Prior art keywords
group
conjugate
cancer
prodrug
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210334259.4A
Other languages
English (en)
Chinese (zh)
Inventor
塞巴斯蒂安·帕波
伊莎贝尔·奥帕林斯基
布丽奇特·勒努
蒂博·莱吉甘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Poitiers
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite de Poitiers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite de Poitiers filed Critical Centre National de la Recherche Scientifique CNRS
Publication of CN114917358A publication Critical patent/CN114917358A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202210334259.4A 2014-02-07 2015-02-06 用于治疗癌症和炎症性疾病的偶联物和前药 Pending CN114917358A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR1450956A FR3017298B1 (fr) 2014-02-07 2014-02-07 Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires
FR1450956 2014-02-07
CN201580018638.0A CN106573071A (zh) 2014-02-07 2015-02-06 用于治疗癌症和炎症性疾病的偶联物和前药
PCT/IB2015/050914 WO2015118497A1 (fr) 2014-02-07 2015-02-06 Conjugués et pro-drogues pour le traitement du cancer et de maladies inflammatoires

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580018638.0A Division CN106573071A (zh) 2014-02-07 2015-02-06 用于治疗癌症和炎症性疾病的偶联物和前药

Publications (1)

Publication Number Publication Date
CN114917358A true CN114917358A (zh) 2022-08-19

Family

ID=50829100

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210334259.4A Pending CN114917358A (zh) 2014-02-07 2015-02-06 用于治疗癌症和炎症性疾病的偶联物和前药
CN201580018638.0A Pending CN106573071A (zh) 2014-02-07 2015-02-06 用于治疗癌症和炎症性疾病的偶联物和前药

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580018638.0A Pending CN106573071A (zh) 2014-02-07 2015-02-06 用于治疗癌症和炎症性疾病的偶联物和前药

Country Status (9)

Country Link
US (1) US10293021B2 (https=)
EP (2) EP3139963B1 (https=)
JP (1) JP6721512B2 (https=)
CN (2) CN114917358A (https=)
CA (1) CA2938501C (https=)
DK (1) DK3139963T3 (https=)
ES (1) ES2843798T3 (https=)
FR (1) FR3017298B1 (https=)
WO (1) WO2015118497A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6948708B2 (ja) 2015-06-19 2021-10-13 センチュリオン バイオファーマ コーポレイション 薬物制御放出のための送達系
WO2017058808A1 (en) * 2015-10-02 2017-04-06 Sirenas Llc Anti-cancer compounds and conjugates thereof
CN108779146B (zh) * 2016-03-29 2022-03-18 东丽株式会社 肽衍生物及其用途
US11666657B2 (en) 2017-05-16 2023-06-06 Universite De Strasbourg Protein-drug conjugates and their use in the treatment of cancers
EP4344747A3 (en) * 2017-11-30 2024-07-03 LadRx Corporation Albumin-binding prodrugs of auristatin e derivatives
KR102840665B1 (ko) * 2018-04-03 2025-07-30 신디비아 세포독성 약물의 접합체 및 상기 접합체의 전구약물 형태
CN114173877B (zh) * 2019-05-06 2024-12-10 施科友智能化学疗法公司 用于治疗癌症的新的治疗载体和前药
FR3126982B1 (fr) * 2021-09-14 2023-09-15 Centre Nat Rech Scient Vecteurs ciblant la beta-d-n-acetylglucosaminidase
CN116077674B (zh) * 2022-12-26 2025-03-25 北京大学 生物分子-聚氮氧化物偶联物及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
DK3248613T3 (da) * 2005-07-18 2022-03-14 Seagen Inc Beta-glucuronid-lægemiddel-linkerkonjugater
FR2960153B1 (fr) 2010-05-20 2012-08-17 Centre Nat Rech Scient Nouveaux bras autoreactifs et prodrogues les comprenant

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ISABELLE TRANOY-OPALINSKI等: "β-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: An update", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》, vol. 74, pages 308 - 311 *
KAI TEMMING等: "Evaluation of RGD-Targeted Albumin Carriers for Specific Delivery of Auristatin E to Tumor Blood Vessels", 《BIOCONJUGATE CHEMISTRY》, vol. 17, no. 6, pages 1385 - 1394, XP055553525, DOI: 10.1021/bc060087z *
THIBAUT LEGIGAN等: "The First Generation of β-Galactosidase-Responsive Prodrugs Designed for the Selective Treatment of Solid Tumors in Prodrug Monotherapy", 《ANGEWANDTE COMMUNICATIONS》, vol. 51, no. 46, pages 11606 - 11610, XP055080092, DOI: 10.1002/anie.201204935 *

Also Published As

Publication number Publication date
JP6721512B2 (ja) 2020-07-15
DK3139963T3 (da) 2020-10-26
FR3017298A1 (fr) 2015-08-14
ES2843798T3 (es) 2021-07-20
EP3139963B1 (fr) 2020-10-07
CN106573071A (zh) 2017-04-19
EP3139963A1 (fr) 2017-03-15
CA2938501A1 (fr) 2015-08-13
WO2015118497A1 (fr) 2015-08-13
JP2017506628A (ja) 2017-03-09
US10293021B2 (en) 2019-05-21
EP3766510A1 (fr) 2021-01-20
FR3017298B1 (fr) 2016-03-04
CA2938501C (fr) 2022-04-05
US20170095525A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
JP6721512B2 (ja) がん及び炎症性疾患の治療のための結合体及びプロドラッグ
CN107108694B (zh) 含叔胺药物物质的靶向递送
TWI851531B (zh) 具有改善之生理化學性質之具自我穩定連接子之藥物結合物
KR20190126314A (ko) 암-선택적 표지화 및 표적화를 위한 트리거 활성화 가능한 당 접합체
US12454527B2 (en) Conjugate monomethyl auristatin E to obtain a composition for treatment of prostate cancer
EP2740493A1 (en) Conjugates of the B-subunit of Shiga toxin for anticancer therapies
HK1236815A1 (en) Conjugates and prodrugs for treating of cancer and inflammatory diseases
US12459928B2 (en) Therapeutic vectors and prodrugs for treating cancers
WO2025261479A1 (zh) 以丁二酰基为连接链的偶联物及其制备方法和用途
HK40079820B (zh) 含叔胺药物物质的靶向递送
HK40065994A (zh) 含叔胺药物物质的靶向递送
HK40079820A (en) Targeted delivery of tertiary amine-containing drug substances
JP2025507676A (ja) ヒドロキシアパタイト標的造影および療法のための、コンジュゲート、組成物および方法
EP4401787A1 (fr) Vecteurs ciblant la beta-d-n-acetylglucosaminidase

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination